N-[3,5-Bis(trifluoromethyl)phenyl]-N′-[5-bromo-2-(2H-tetrazol-5-yl)phenyl]urea

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H9BrF6N6O
Molecular Weight	495.177
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of N-[3,5-Bis(trifluoromethyl)phenyl]-N′-[5-bromo-2-(2H-tetrazol-5-yl)phenyl]urea

Structure Search

SMILES

FC(F)(F)C1=CC(=CC(NC(=O)NC2=C(C=CC(Br)=C2)C3=NN=NN3)=C1)C(F)(F)F

InChI

InChIKey=OQRAKHDEGGGWQO-UHFFFAOYSA-N

InChI=1S/C16H9BrF6N6O/c17-9-1-2-11(13-26-28-29-27-13)12(6-9)25-14(30)24-10-4-7(15(18,19)20)3-8(5-10)16(21,22)23/h1-6H,(H2,24,25,30)(H,26,27,28,29)

HIDE SMILES / InChI

Molecular Formula	C16H9BrF6N6O
Molecular Weight	495.177
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=2ahUKEwiH49SesrbhAhWJxMQBHTUYA84QFjACegQIAxAC&url=http%3A%2F%2Fneurosearch.com%2FAdmin%2FPublic%2FDownload.aspx%3Ffile%3DFiles%252FFiler%252FPdf%252F20041117_uk.pdf&usg=AOvVaw3ZSUqCxya0JC5vbaBpS533 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/740c87068ac89f325b63a9dbeed2885b.html | https://www.ncbi.nlm.nih.gov/pubmed/18321227 | https://adisinsight.springer.com/drugs/800014775

NS-3728 (Endovion) is an orally active chloride channel blocker for the treatment of cancer. Endovion was originally discovered by NeuroSearch. In August 2004, NeuroSearch entered into a collaboration with TopoTarget to develop its compound Endovion, an orally active chloride channel blocker for the treatment of cancer. Endovion blocks a certain subtype of chloride ion channels important for cell division, cell migration and the formation of new blood vessels (angiogenesis). Endovion has shown efficacy in preclinical cancer models. The compound has completed Phase I clinical trials in 92 subjects. Endovion had been in phase I clinical trials for the treatment of sickle cell anemia and solid tumours. TopoTarget has discontinued development of Endovion for use in glioblastoma. It was discontinued as supplementary preclinical trials did not support its activity as an anticancer agent. Early studies as an anti sickling agent were discontinued due to higher costs than first estimated for the clinical programme.

Originator

Approval Year

PubMed

Title	Date	PubMed
Inhibition of the endogenous volume-regulated anion channel (VRAC) in HEK293 cells by acidic di-aryl-ureas.	2003 Nov 15	14724745
Chloride channel blockers inhibit iNOS expression and NO production in IFNgamma-stimulated microglial BV2 cells.	2009 Jul 24	19446535

Patents

Sample Use Guides

In Vivo Use Guide

The in vivo anti-tumor effect of NS-3728 on C6 glioma cells given either as monotherapy (40 mg/kg/day) or in combination with temozolomide (Temodal, 25 or 5 mg/kg/day) was tested in two separate experiments, using either the xenograft method or the subcutaneous air sac rat model. Oral administration of NS-3728 (40 mg/kg/day) in combination with temozolomide (25 mg/kg/day) resulted in a significant reduction of growth rate, whereas neither NS-3728 (40 mg/kg/day) nor temozolomide (25 mg/kg/day) exhibited any significant anti-tumor effect when given as monotherapy

Route of Administration: Oral

In Vitro Use Guide

NS-3728 inhibited the VRAC current in HEK293 cells with IC50 value of 0.40 uM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 20:10:35 GMT 2023` Edited by `admin` on `Sat Dec 16 20:10:35 GMT 2023`
Record UNII	9H4XH6M8MU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

N-[3,5-Bis(trifluoromethyl)phenyl]-N′-[5-bromo-2-(2H-tetrazol-5-yl)phenyl]urea

Systematic Name

English

Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N′-[5-bromo-2-(2H-tetrazol-5-yl)phenyl]-

Systematic Name

English

Code System Code Type Description

FDA UNII

9H4XH6M8MU

Created by admin on Sat Dec 16 20:10:35 GMT 2023 , Edited by admin on Sat Dec 16 20:10:35 GMT 2023

PRIMARY

PUBCHEM

71587684

Created by admin on Sat Dec 16 20:10:35 GMT 2023 , Edited by admin on Sat Dec 16 20:10:35 GMT 2023

PRIMARY

CAS

2597341-93-8

Created by admin on Sat Dec 16 20:10:35 GMT 2023 , Edited by admin on Sat Dec 16 20:10:35 GMT 2023

PRIMARY